Adjuvanted Influenza Vaccine Technology
flu360® connects you with flu vaccine innovation to address the challenges of the flu that can disproportionately affect adults 65 years and older.1
flu360® connects you with flu vaccine innovation to address the challenges of the flu that can disproportionately affect adults 65 years and older.1
Adults 65+ experience age-related decline of the immune system and thus may be less able to mount a sufficient immune response to vaccination, leaving them more vulnerable to influenza infection and its complications.2
This occurs when circulating influenza strains do not match the WHO-selected strains contained in the vaccine. Most often, it is due to mutations from antigenic drift or egg adaptation. It can also occur when the prevalent circulating influenza strains are different from WHO predictions.3,4
An adjuvant is a substance added to a vaccine to boost the immune response.5
This is a conceptualization of the mechanism of action (MOA) of an MF59® adjuvanted influenza vaccine and a standard-dose, non-adjuvanted influenza vaccine.
Adding an adjuvant can make a difference for those patients 65 years and older.1
Learn more about our adjuvanted influenza vaccineInfluenza vaccine effectiveness continues to be challenging as influenza disproportionately affects adults 65 years and older.1
Learn more about the burden of influenzaReferences.1. Centers for Disease Control and Prevention. Flu & people 65 years and older. Accessed February 12, 2021. https://www.cdc.gov/flu/highrisk/65over.htm 2. Monto AS, Ansaldi F, Aspinall R, et al. Influenza control in the 21st century: optimizing protection of older adults. Vaccine. 2009 27(37):5043-5053. doi:10.1016/j.vaccine.2009.06.032 3. Paules CI, Sullivan SG, Subbarao K, Fauci AS. Chasing seasonal influenza - the need for a universal influenza vaccine. N Engl J Med. 2018 378(1):7-9. doi:10.1056/NEJMp1714916 4. Zost SJ, Parkhouse K, Gumina ME, et al. Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains. Proc Natl Acad Sci USA. 2017 114(47):12578-12583. doi:10.1073/pnas.1712377114 5. Garç on N, Leroux-Roels G, Cheng WF. Vaccine adjuvants. Understanding modern vaccines: Perspectives in vaccinology. 2011 1(1):89-113. 6. O'Hagan DT, Ott GS, De Gregorio E, Seubert A. The mechanism of action of MF59—an innately attractive adjuvant formulation. Vaccine. 2012 30(29):4341-4348. doi:10.1016/j.vaccine.2011.09.061 7. O'Hagan DT, Ott GS, Nest GV, Rappuoli R, Del Giudice G. The history of MF59® adjuvant: a phoenix that arose from the ashes. Expert Rev Vaccines. 2013 12(1):13-30. doi:10.1586/erv.12.140 8. Banzhoff A, Pellegrini M, Del Giudice G, Fragapane E, Groth N, Podda A. MF59-adjuvanted vaccines for seasonal and pandemic influenza prophylaxis. Influenza Other Respir Viruses. 2008 2(6):243-249. doi:10.1111/j.1750-2659.2008.00059.x